Autophagy Dual Activation is a synergistic therapeutic strategy that simultaneously enhances autophagy (the cell's garbage disposal system) and proteostasis network (protein folding quality control) to clear pathogenic protein aggregates in neurodegenerative diseases.
Autophagy (macroautophagy) involves the formation of double-membrane autophagosomes that engulf protein aggregates and damaged organelles, delivering them to lysosomes for degradation. Key targets include:
- mTOR inhibition: Rapamycin and rapalogs (e.g., everolimus) activate ULK1 complex
- Beclin-1 activation: PI3K class III complexes that initiate nucleation
- LC3 lipidation: ATG proteins that decorate autophagosomes
- Lysosomal enhancement: TFEB (transcription factor EB) agonists
The proteostasis network maintains protein folding quality control through:
- Molecular chaperones: Hsp70, Hsp90 systems that refold misfolded proteins
- Ubiquitin-proteasome system (UPS): Degrades ubiquitinated proteins
- ER-associated degradation (ERAD): Clears misfolded proteins from ER
- Unfolded protein response (UPR): Adaptive stress responses
Dual activation works because:
- Autophagy clears large aggregates (>MDa) that proteasome cannot handle
- Proteasome handles soluble misfolded proteins more efficiently
- Chaperones can redirect proteins away from aggregation toward refolding
- Combined approach addresses both existing aggregates and ongoing misfolding stress
- Aβ oligomers and tau tangles are autophagy substrates
- mTOR inhibition reduces Aβ and tau pathology in mouse models
- TFEB activation enhances lysosomal clearance of Aβ
- Alpha-synuclein aggregates cleared by autophagy
- PINK1/Parkin mitophagy pathway critical for mitochondrial quality
- GBA1 mutations (gaucher) impair autophagosome-lysosome fusion
- TDP-43 aggregates cleared by autophagy
- SOD1 mutant clearance enhanced by autophagy induction
- C9orf72 mutations affect autophagosome formation
- Mutant huntingtin protein is autophagy substrate
- mTOR inhibition reduces polyglutamine aggregates
- Autophagy enhancers show promise in HD models
¶ Drug Candidates
| Drug |
Mechanism |
Status |
Indication |
| Rapamycin |
mTOR inhibitor |
Phase 2/3 |
AD, PD |
| Everolimus |
mTOR inhibitor |
Phase 2 |
AD |
| Lithium |
IMPase inhibitor |
Phase 2 |
AD, ALS |
| Drug |
Mechanism |
Evidence |
| Carbamazepine |
mTOR inhibitor |
Reduces Aβ in mice |
| Trehalose |
mTOR-independent autophagy |
Clears alpha-synuclein |
| Rapamycin |
mTOR inhibitor |
Reduces tau in 3xTg-AD |
| SB203580 |
p38 inhibitor |
Enhances autophagy |
- Hsp90 inhibitors (geldanamycin analogs) + autophagy inducers
- Rationale: Redirects proteins from aggregation to refolding
- Proteasome inhibitors (bortezomib) + autophagy enhancers
- Rationale: Compensatory autophagy when proteasome overloaded
- Aggregation inhibitors + autophagy enhancers
- Rationale: Prevent new aggregates while clearing existing ones
- Autophagy induction can be non-selective - may degrade essential proteins
- mTOR inhibition has immunosuppressive effects - long-term safety concerns
- Optimal timing unclear - may need early intervention before irreversible damage
- Biomarkers lacking - difficult to monitor autophagy activation in humans
- Human biomarker development for autophagy flux
- Brain-penetrant autophagy enhancers needed
- Optimal combination regimens undefined
- Long-term safety data lacking
| Dimension |
Score |
Rationale |
| Novelty |
8/10 |
Dual targeting autophagy + proteostasis is innovative; many single-target approaches exist |
| Mechanistic Rationale |
9/10 |
Strong preclinical evidence; synergistic clearance of aggregates well-documented |
| Addresses Root Cause |
9/10 |
Directly targets protein aggregate clearance, a core pathological mechanism |
| Delivery Feasibility |
5/10 |
BBB-penetrant autophagy inducers challenging; repurposing candidates exist |
| Safety Plausibility |
6/10 |
mTOR inhibitors have track record; off-target effects possible |
| Combinability |
8/10 |
Highly compatible with most neurodegenerative therapies |
| Biomarker Availability |
7/10 |
Autophagy flux biomarkers, aggregate clearance markers available |
| De-risking Path |
7/10 |
FDA-approved autophagy modulators exist (rapamycin, everolimus) |
| Multi-disease Potential |
9/10 |
High: AD, PD, ALS, HD, FTD, prion diseases |
| Patient Impact |
8/10 |
Could slow progression in proteinopathies; broad applicability |
Total: 76/100
- Dual mechanism compound screening: Establish high-throughput screen for compounds that simultaneously activate autophagy (via TFEB nuclear translocation) and enhance proteasome activity (via UPS reporter). Primary hit confirmation in iPSC-derived neurons from AD/PD patients.
- Staggered dosing optimization: Test staggered vs. continuous dosing protocols in 2D neuronal cultures and 3D brain organoids. Measure autophagic flux (LC3-II turnover), proteasome activity (chymotrypsin-like activity), and cell viability over 2-4 weeks.
- Aggregate clearance assays: Use alpha-synuclein preformed fibrils, Aβ oligomers, and tau seeds in neuronal models. Quantify aggregate reduction via ELISA, Western blot, and immunohistochemistry at 1, 2, and 4 weeks.
- Biomarker development: Validate autophagosome (LC3, p62) and proteasome (PSMA5) markers in conditioned media as pharmacodynamic biomarkers. Correlate with aggregate clearance in patient-derived cells.
- Combination synergy testing: Test approved autophagy inducers (rapamycin, trehalose) combined with proteasome enhancers (PI-083, carfilzomib) in vivo using APP/PS1 and alpha-synuclein transgenic mice.
- Patient population enrichment: Target early-stage AD (MMSE 20-26) or PD (Hoehn & Yahr 1-2) patients with confirmed biomarker evidence of protein aggregation (amyloid PET positive for AD, alpha-synuclein RT-QuIC positive for PD).
- Staggered dosing trial design:
- Phase 1b: Single ascending dose with PK/PD biomarker cohort (autophagy/proteasome markers in peripheral blood mononuclear cells)
- Phase 2a: 12-week staggered dosing (3 weeks on, 1 week off) vs. continuous dosing, with CSF sampling for autophagic flux biomarkers
- Endpoint selection:
- Primary: Change in CSF neurofilament light chain (NfL) as marker of neuronal injury
- Secondary: Amyloid/tau PET, cognitive battery (ADAS-Cog13, MoCA), motor scores (MDS-UPDRS for PD)
- Safety monitoring: Monitor for immunosuppression (rapamycin class effect), liver function (proteasome inhibitor class effect), and autophagy-related adverse events.
- Rapamycin/rapalog developers: Contact Novartis (rapamycin), Pfizer (rapalog program) for partnership on CNS-optimized formulations
- TFEB activator programs: Reach out to Neurocrine Biosciences, Denali Therapeutics (LTG-001, LTI-291) for combination therapy studies
- Proteostasis network companies: Engage with Prothelia (proteostasis modulators), Salvina (Hsp90 inhibitors) for dual-mechanism approaches
- Biomarker companies: Partner with Fujirebio, Roche for validated autophagic flux biomarker assays in CSF
| Phase |
Timeline |
Activities |
Cost Estimate |
| Phase 1: Target Validation & Compound Screening |
Months 1-12 |
Dual-mechanism compound screen, iPSC neuron validation, staggered dosing optimization |
$3.5-5M |
| Phase 2: Preclinical Development |
Months 10-24 |
IND-enabling studies, GLP toxicology ( rodents, non-human primates), biomarker assay validation |
$8-14M |
| Phase 3: Clinical Trial Design & Execution |
Months 24-48 |
Phase 1b/2a trial execution, patient enrollment, interim biomarker analysis |
$15-28M |
| Total Program |
36-48 months |
|
$26.5-47M |
- Month 6: Complete compound screen, select 2-3 lead candidates
- Month 12: Complete iPSC validation, file pre-IND meeting request
- Month 18: Complete GLP toxicology, submit IND
- Month 24: Phase 1b initiation
- Month 36: Phase 2a interim analysis
- Month 48: End of Phase 2a, go/no-go decision
- Optimistic (60% probability): Single compound with dual mechanism identified, smooth IND, biomarker-driven enrollment → $26.5M
- Base case (25% probability): Requires combination approach, IND delayed 6 months → $36M
- Conservative (15% probability): Significant reformulation needed, additional indication-specific trials → $47M
- Banner Sun Health Research Institute (Arizona) — Autophagy expertise, Lewy body disease cohort
- University of Pennsylvania — Marian S. Ware Alzheimer Program, proteostasis research
- University of Cambridge — MRC Dementia Research Institute, TFEB biology
- Karolinska Institutet — Nordic Brain Bank, PD cohorts